NASDAQ:CGEN - Compugen Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $20.71
  • Forecasted Upside: 149.72 %
  • Number of Analysts: 7
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 7 Buy Ratings
  • 0 Strong Buy Ratings
$8.30
▲ +0.13 (1.59%)
1 month | 3 months | 12 months
Get New Compugen Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CGEN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CGEN

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$20.71
▲ +149.72% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for Compugen in the last 3 months. The average price target is $20.71, with a high forecast of $28.00 and a low forecast of $18.00. The average price target represents a 149.72% upside from the last price of $8.30.
Buy
The current consensus among 7 contributing investment analysts is to buy stock in Compugen. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/12/2019
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/11/2019
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/10/2020
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/8/2020
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/6/2020
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/5/2020
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/3/2021
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/5/2021

Latest Recommendations

  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/19/2020SVB LeerinkBoost Price TargetOutperform$15.00 ➝ $19.00High
i
Rating by D. Graybosch at SVB Leerink LLC
8/11/2020Jefferies Financial GroupReiterated RatingBuy$20.00Low
i
7/30/2020OppenheimerInitiated CoverageBuy$19.00High
i
Rating by Mark Breidenbach at Oppenheimer Holdings Inc.
5/26/2020JMP SecuritiesInitiated CoverageOutperform$18.00High
i
5/13/2020Stifel NicolausInitiated CoverageBuy$19.00High
i
5/7/2020SVB LeerinkInitiated CoverageOutperform$15.00High
i
Rating by D. Graybosch at SVB Leerink LLC
4/28/2020SunTrust BanksBoost Price TargetPositive ➝ Buy$16.00 ➝ $22.00High
i
4/27/2020OppenheimerReiterated RatingBuy$15.00High
i
4/22/2020Roth CapitalInitiated CoverageBuy$28.00Medium
i
Rating by T. Butler at Roth Capital
3/24/2020SunTrust BanksInitiated CoverageBuy$16.00High
i
2/21/2020Cantor FitzgeraldReiterated RatingOverweight$10.00 ➝ $13.00High
i
Rating by V. Kumar at Cantor Fitzgerald
1/15/2020Cantor FitzgeraldInitiated CoverageOverweight$10.00High
i
Rating by V. Kumar at Cantor Fitzgerald
2/26/2019OppenheimerSet Price TargetBuy$9.00High
i
Rating by Mark Breidenbach at Oppenheimer Holdings Inc.
11/7/2018OppenheimerSet Price TargetBuy$9.00Medium
i
Rating by Mark Breidenbach at Oppenheimer Holdings Inc.
3/29/2018CIBCInitiated CoverageOutperform ➝ OutperformLow
i
3/29/2018OppenheimerInitiated CoverageOutperform$9.00High
i
5/19/2017(FBRC)Set Price TargetBuy$14.00High
i
Rating by Vernon Bernardino at (FBRC)
3/4/2017(FBRC)Reiterated RatingBuyN/A
i
Rating by Vernon Bernardino at (FBRC)
2/16/2017(FBRC)Reiterated RatingBuy$14.00N/A
i
Rating by Vernon Bernardino at (FBRC)
12/8/2016(FBRC)Set Price TargetBuy$14.00N/A
i
Rating by Vernon Bernardino at (FBRC)
11/29/2016(FBRC)Reiterated RatingBuy$14.00N/A
i
Rating by Vernon Bernardino at (FBRC)
11/15/2016(FBRC)Reiterated RatingBuyN/A
i
Rating by Vernon Bernardino at (FBRC)
6/22/2016(FBRC)Reiterated RatingBuyN/A
i
Rating by Vernon Bernardino at (FBRC)
5/12/2016(FBRC)Reiterated RatingBuyN/A
i
Rating by Vernon Bernardino at (FBRC)
3/9/2016JPMorgan Chase & Co.Lower Price TargetMarket Outperform$14.00 ➝ $11.00N/A
i
3/9/2016JMP SecuritiesLower Price TargetMarket Outperform$14.00 ➝ $11.00N/A
i
(Data available from 3/6/2016 forward)
Compugen logo
Compugen Ltd., a clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; BAY 1905254, a therapeutic antibody targeting ILDR2, which is in Phase I clinical study in patients with solid tumors; and COM902, a therapeutic antibody targeting TIGIT. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused primarily on myeloid targets. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics for antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.
Read More

Today's Range

Now: $8.30
$7.10
$8.41

50 Day Range

MA: $12.15
$8.16
$13.77

52 Week Range

Now: $8.30
$5.94
$19.90

Volume

2,849,023 shs

Average Volume

1,383,792 shs

Market Capitalization

$567.54 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.52

Frequently Asked Questions

What sell-side analysts currently cover shares of Compugen?

The following Wall Street research analysts have issued reports on Compugen in the last year: Jefferies Financial Group Inc., JMP Securities, Oppenheimer Holdings Inc., Roth Capital, Stifel Nicolaus, SunTrust Banks, Inc., SVB Leerink LLC, and Zacks Investment Research.
View the latest analyst ratings for CGEN.

What is the current price target for Compugen?

7 Wall Street analysts have set twelve-month price targets for Compugen in the last year. Their average twelve-month price target is $20.71, suggesting a possible upside of 149.7%. Roth Capital has the highest price target set, predicting CGEN will reach $28.00 in the next twelve months. JMP Securities has the lowest price target set, forecasting a price of $18.00 for Compugen in the next year.
View the latest price targets for CGEN.

What is the current consensus analyst rating for Compugen?

Compugen currently has 7 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe CGEN will outperform the market and that investors should add to their positions of Compugen.
View the latest ratings for CGEN.

What other companies compete with Compugen?

How do I contact Compugen's investor relations team?

Compugen's physical mailing address is Azrieli Center 26 Harokmim Street Building D, Holon L3, 5885849. The biotechnology company's listed phone number is 972-3765-8585 and its investor relations email address is [email protected] The official website for Compugen is www.cgen.com.